Methods of assessing purity of cytisine using gradient chromatography at multiple wavelengths is provided herein.

An operational condition of a liquid chromatography (LC) system (2110) is detected and displayed without user intervention. A plurality of pressure measurements over time are received from a pressure sensor (2119) of the LC system. A processor (2140) calculates values from the measurements for six parameters including a beginning pressure (P.sub.B), an ending pressure (P.sub.E), an average pressure (T.sub.1) for a first half of the separation, an average pressure (T.sub.2) for a second half of the separation, a ratio T.sub.1/P.sub.B, and a ratio T.sub.2/P.sub.B. The values of the six parameters are classified as one of one or more operational conditions of the LC system using a machine learning model. The machine learning model is created from values of the six parameters calculated from known separations for each of the one or more operational conditions. The operational condition found from the classification is displayed on a display device (2141).

Provided is a method to initiate and analyze chemical derivatives formed from pyrotechnic smoke reactions. Milligram quantities of a lab-scale pyrotechnic smoke composition are reacted by encapsulation with a metal probe that is rapidly heated, which then sublimes the organic dye, allowing for the testing of all of the gas-phase products for identification by pyrolysis-gas chromatography-mass spectrometry. The thermally decomposed ingredients and new side product derivatives are identified at lower relative abundances compared to the intact organic dye. Any remaining residues within the thermal probe are optionally reconstituted into solution for further analysis by liquid chromatography-mass spectrometry if desired. The results are processed via a machine learning quantitative structure-activity relationship model that provides data related to health and environmental hazards.

The present disclosure discusses a method of separating a sample of tyrosine kinase inhibitors or metabolites of tyrosine kinase inhibitors which includes injecting the sample into the chromatographic system having one or more low-bind coated surfaces along the flow path; flowing the sample through the chromatographic system; separating the sample; and analyzing the separated sample. Consequently, the sample does not bind to the low-binding surface coatings (e.g., alkylsilyl coatings) of the flow path. The applied coating can reduce peak tailing and decrease carryover for tyrosine kinase inhibitor samples during chromatographic analysis.

A method for analyzing single cells by mass spectrometry includes the steps of providing a plurality of cells in a liquid medium and placing the cells and liquid medium in a single cell isolation and ejection system. Liquid medium containing a single cell is released from the single cell isolation and ejection system. The liquid medium and single cell are captured in a capture probe containing a flowing capture probe solvent. The cell is lysed by a lysis inducer in the capture probe to disperse single cell components into the medium. The lysed single cell components are transported to a mass spectrometer, where the lysed single cell components entering the mass spectrometer are spatially and temporally separated from any dispersed components of another single cell from the sample entering the mass spectrometer. Mass spectrometry is conducted on the lysed single-cell components. A system for analyzing single cells by mass spectrometry is also disclosed.

An analyzer is provided with a device body for analyzing a sample and an information processing apparatus for controlling the operation of the device body. The information processing apparatus is configured to collect an operation log indicating an internal operation of the device body. In the operation log, information indicating an operation command issued by the information processing apparatus and information indicating an operation content performed by the device body in response to the operation command are associated on a one-to-one basis.

The present disclosure discusses a method of separating a sample (e.g., pharmaceutical drug, genotoxic impurity, biomarker, and/or biological metabolite) including coating a metallic flow path of a chromatographic system; injecting the sample into the chromatographic system; flowing the sample through the chromatographic system; separating the sample; and analyzing the separated sample using mass spectroscopy. In some examples, the coating applied to the surfaces defining the flow path is non-binding with respect to the sample—and the separated sample. Consequently, the sample does not bind to the low-binding surface of the coating of the flow path. The applied coating can increase the chromatographic peak area for the sample of the chromatographic system.

The present disclosure relates to the determination of analytes in a sample using chromatography. The present disclosure provides methods of separating an analyte from a sample. A mobile phase is flowed through a chromatography column. The mobile phase includes about 0.005% (v/v) to about 2.50% (v/v) difluoroacetic acid and less than about 100 ppb of any individual impurity, especially metal impurities. A sample including the analyte is injected into the mobile phase. The analyte is separated from the sample.

The present disclosure relates to methods of modifying complex extracts such that components or mixtures of components are selectively removed or added, thus providing a complex mixture that does not naturally occur with a refined or a tuned therapeutic or nutraceutical effect. In various aspects, the complex extract can be an extract obtained from one or more plants, e.g., an extract obtained from green tea leaves. The present disclosure pertains to compositions obtained by the disclosed methods, nutraceutical compositions comprising same, pharmaceutical compositions comprising same, and methods of treating various conditions, including physiological dysfunctions associated with elevated reactive oxygen species and/or inflammatory molecule, e.g., TNFα, expression using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Examples are directed toward collecting, by a LC-MS device, a full scan of ion chromatograms of a sample. The LC-MS device determines observed ions contained in the full scan, based on mass-to-charge ratios (m/z), and determines, for a formation curve of an observed ion, a formation point at which fifty percent of the observed ion has formed. The LC-MS device determines a fragmentation curve of a precursor ion, based on a fragmentation point of the fragmentation curve equivalent to the formation point at which fifty percent of the precursor ion has fragmented, and identifies the precursor ion by referencing the LC-MS library to confirm that the observed ion is a product of the fragmentation of the precursor ion. The LC-MS device indicates a goodness of fit between the fragmentation curve, as observed, and a model fragmentation curve, as stored in the LC-MS library.